# Safety and Tolerability of Nexvax2 in Subjects With Celiac Disease

> **NCT02528799** · PHASE1 · COMPLETED · sponsor: **ImmusanT, Inc.** · enrollment: 38 (actual)

## Conditions studied

- Celiac Disease

## Interventions

- **BIOLOGICAL:** Nexvax2
- **BIOLOGICAL:** Nexvax2 placebo

## Key facts

- **NCT ID:** NCT02528799
- **Lead sponsor:** ImmusanT, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08
- **Primary completion:** 2017-01-06
- **Final completion:** 2017-01-06
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2018-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02528799

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02528799, "Safety and Tolerability of Nexvax2 in Subjects With Celiac Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02528799. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*